NCT03683433 2026-03-05Enasidenib and Azacitidine in Treating Patients With Recurrent or Refractory Acute Myeloid Leukemia and IDH2 Gene MutationM.D. Anderson Cancer CenterPhase 2 Recruiting50 enrolled
NCT03383575 2026-02-17Azacitidine and Enasidenib in Treating Patients With IDH2-Mutant Myelodysplastic SyndromeM.D. Anderson Cancer CenterPhase 2 Recruiting63 enrolled